Market overview
The global in vitro diagnostics market is worth USD 108 bn in 2026 and is forecast to reach USD 184 bn by 2036, growing at a 5.5% CAGR. United States is the largest country market and Immunoassay is the largest by technology segment.
| Scope | Reagents, instruments and software used to test human samples outside the body for disease detection and monitoring: immunoassay, clinical chemistry, molecular, hematology, microbiology, coagulation and point-of-care tests. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 102 bn |
| Value 2026 | USD 108 bn |
| Value 2036 | USD 184 bn |
| CAGR 2026-2036 | 5.5% |
| Volume 2026 | 41,782 million tests |
| Volume 2036 | 64,610 million tests |
| Average price 2026 | USD 2.58 per test |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
In Vitro Diagnostics market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 108 bn |
| 2027 | USD 114 bn |
| 2028 | USD 120 bn |
| 2029 | USD 126 bn |
| 2030 | USD 133 bn |
| 2031 | USD 141 bn |
| 2032 | USD 148 bn |
| 2033 | USD 157 bn |
| 2034 | USD 165 bn |
| 2035 | USD 174 bn |
| 2036 | USD 184 bn |
In Vitro Diagnostics market segmentation
By technology
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Immunoassay | 30.0% | 29.2% | USD 32.3 bn | 5.2% |
| Clinical chemistry | 17.0% | 13.7% | USD 18.3 bn | 3.2% |
| Molecular diagnostics | 20.0% | 24.6% | USD 21.5 bn | 7.7% |
| Point of care | 13.0% | 14.6% | USD 14.0 bn | 6.7% |
| Hematology and coagulation | 8.0% | 6.8% | USD 8.6 bn | 3.7% |
| Microbiology and others | 12.0% | 11.1% | USD 12.9 bn | 4.7% |
By product
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Reagents and consumables | 68.0% | 67.2% | USD 73.2 bn | 5.4% |
| Instruments | 22.0% | 19.8% | USD 23.7 bn | 4.4% |
| Software and services | 10.0% | 13.1% | USD 10.8 bn | 8.4% |
By application
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Infectious disease | 28.0% | 26.3% | USD 30.1 bn | 4.8% |
| Oncology | 14.0% | 18.3% | USD 15.1 bn | 8.3% |
| Diabetes | 12.0% | 11.8% | USD 12.9 bn | 5.3% |
| Cardiology | 9.0% | 8.9% | USD 9.7 bn | 5.3% |
| Autoimmune and others | 37.0% | 34.8% | USD 39.8 bn | 4.8% |
By testing location
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Central laboratory | 56.0% | 52.0% | USD 60.3 bn | 4.7% |
| Point of care | 24.0% | 24.0% | USD 25.8 bn | 5.5% |
| Home and self-testing | 20.0% | 24.0% | USD 21.5 bn | 7.4% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospital laboratories | 40.0% | 38.0% | USD 43.0 bn | 5.0% |
| Independent laboratories | 32.0% | 32.0% | USD 34.4 bn | 5.5% |
| Clinics and physician offices | 16.0% | 16.0% | USD 17.2 bn | 5.5% |
| Academic and research | 12.0% | 14.0% | USD 12.9 bn | 7.1% |
Top 25 countries for in vitro diagnostics by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 78.5% of 2026 revenue and the 25 countries below together hold 94.4%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 38.7 bn | 36.0% | USD 64.7 bn | 5.3% |
| 2 | China | USD 12.9 bn | 12.0% | USD 23.7 bn | 6.3% |
| 3 | Germany | USD 6.5 bn | 6.0% | USD 10.3 bn | 4.8% |
| 4 | Japan | USD 6.5 bn | 6.0% | USD 9.7 bn | 4.2% |
| 5 | France | USD 4.3 bn | 4.0% | USD 6.6 bn | 4.4% |
| 6 | Italy | USD 3.2 bn | 3.0% | USD 5.0 bn | 4.4% |
| 7 | United Kingdom | USD 3.2 bn | 3.0% | USD 5.1 bn | 4.8% |
| 8 | India | USD 3.2 bn | 3.0% | USD 7.9 bn | 9.4% |
| 9 | Brazil | USD 3.2 bn | 3.0% | USD 6.2 bn | 6.8% |
| 10 | Spain | USD 2.7 bn | 2.5% | USD 4.2 bn | 4.6% |
| 11 | Canada | USD 1.8 bn | 1.7% | USD 3.0 bn | 4.9% |
| 12 | South Korea | USD 1.6 bn | 1.5% | USD 2.6 bn | 5.0% |
| 13 | Mexico | USD 1.6 bn | 1.5% | USD 3.2 bn | 7.3% |
| 14 | Australia | USD 1.6 bn | 1.5% | USD 2.6 bn | 5.0% |
| 15 | Russia | USD 1.4 bn | 1.3% | USD 2.2 bn | 5.0% |
| 16 | Turkey | USD 1.4 bn | 1.3% | USD 2.8 bn | 7.3% |
| 17 | Netherlands | USD 1.1 bn | 1.1% | USD 1.9 bn | 5.0% |
| 18 | Poland | USD 915 mn | 0.8% | USD 1.5 bn | 4.9% |
| 19 | Saudi Arabia | USD 915 mn | 0.8% | USD 1.9 bn | 7.3% |
| 20 | Taiwan | USD 915 mn | 0.8% | USD 1.5 bn | 4.9% |
| 21 | Indonesia | USD 915 mn | 0.8% | USD 2.2 bn | 9.3% |
| 22 | Switzerland | USD 915 mn | 0.8% | USD 1.5 bn | 4.9% |
| 23 | Thailand | USD 689 mn | 0.6% | USD 1.4 bn | 7.2% |
| 24 | Argentina | USD 689 mn | 0.6% | USD 1.1 bn | 4.8% |
| 25 | Belgium | USD 689 mn | 0.6% | USD 1.1 bn | 4.8% |
| Rest of world | USD 6.0 bn | 5.6% | USD 9.9 bn | 5.2% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Roche
- Abbott
- Siemens Healthineers
- Danaher
- Thermo Fisher Scientific
- bioMerieux
- Qiagen
- DiaSorin
Group 2: Regional and specialist players
- Sysmex
- QuidelOrtho
- Bio-Rad Laboratories
- Becton Dickinson
- Hologic
- Werfen
- Revvity
- Tosoh
- Seegene
- Sekisui Diagnostics
Group 3: Emerging and niche players
- Mindray
- Snibe
- Autobio Diagnostics
- Randox Laboratories
- Getein Biotech
- Boditech Med
- Sansure Biotech
- Wondfo Biotech
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the in vitro diagnostics market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 5.5% is calculated from the resulting values.
The market is divided by technology, by product, by application, by testing location, by end user. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the in vitro diagnostics market?
The global in vitro diagnostics market is estimated at USD 102 bn in 2025 and USD 108 bn in 2026.
How fast will the in vitro diagnostics market grow?
It is forecast to reach USD 184 bn by 2036, a compound annual growth rate of 5.5% from 2026, an increase of USD 76.2 bn.
Which country is the largest market for in vitro diagnostics?
United States is the largest market by revenue at USD 38.7 bn in 2026, 36.0% of the global total. The three largest countries together hold 54.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 9.4% a year from 2026 to 2036.
Which in vitro diagnostics segment is largest?
In the by technology split, Immunoassay is the largest segment with 30.0% of 2026 revenue.
Who are the leading in vitro diagnostics companies?
Global leaders include Roche, Abbott, Siemens Healthineers, Danaher.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Peptide TherapeuticsUSD 110 bn · 12.0% CAGR
- TelemedicineUSD 103 bn · 13.0% CAGR
- Clinical TrialsUSD 118 bn · 7.0% CAGR
- Diabetes DrugsUSD 97.5 bn · 5.0% CAGR
- Generic InjectableUSD 93.3 bn · 6.3% CAGR
- Contract Research OrganizationUSD 91.8 bn · 8.0% CAGR
- Cardiovascular DevicesUSD 83.8 bn · 7.0% CAGR
- Contract Development and Manufacturing OrganizationUSD 140 bn · 8.0% CAGR